Research programme: metabotropic glutamate receptor 2/3 antagonists - BrainCells/Taisho Pharmaceutical

Drug Profile

Research programme: metabotropic glutamate receptor 2/3 antagonists - BrainCells/Taisho Pharmaceutical

Alternative Names: BCI-1038; BCI-1208; BCI-1283; CNS programme - BrainCells/Taisho Pharmaceutical; Neurogenesis-promoting compounds

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Taisho Pharmaceutical
  • Developer BrainCells
  • Class
  • Mechanism of Action Metabotropic glutamate receptor 2 antagonists; Metabotropic glutamate receptor 3 antagonists; Stem cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes - CNS disorders

Highest Development Phases

  • No development reported CNS disorders; Mood disorders

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in CNS-disorders in USA
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Mood disorders in USA
  • 02 Mar 2012 A programme for metabotropic glutamate receptor 2/3 antagonists is available for licensing (\http://www.braincellsinc.com/\)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top